{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:42:17Z","timestamp":1786725737309,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:00:00Z","timestamp":1533513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Children with lupus nephritis particularly, diffuse proliferative and membranous glomerulonephritis, may necessitate potent immunosuppressive medications and occasionally combined therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To report the beneficial effects of tacrolimus (TAC) in children with refractory lupus nephritis from a single tertiary pediatric rheumatology clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This is a retrospective case series of children with refractory lupus nephritis treated with TAC after failure of aggressive immunosuppressive treatment. All patients were evaluated at the time of initiation of TAC and at last follow-up visit by assessing the following response parameters: cSLE Disease Activity Index (SLEDAI), urine protein\/creatinine ratio, urine sediments, serum albumin, complement (C\n                      <jats:sub>3<\/jats:sub>\n                      and C\n                      <jats:sub>4<\/jats:sub>\n                      ), anti-double-stranded DNA (dsDNA) antibody levels, and renal function assessed by glomerular filtration rate (eGFR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Three children (two girls and one boy) with lupus nephritis and persistent nephrotic-range proteinuria failed prednisone treatment as well as sequential treatment of cyclophosphamide, myco- phenolate mofetil (MMF), and rituximab. When TAC was administered along with MMF and prednisone, all patients showed improvement in response parameters, namely, SLEDAI, serum albumin, and proteinuria, and prednisone doses were significantly weaned off and discontinued in two patients. However, eGFR remained stable during the treatment period. TAC was well tolerated, and no adverse effects were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>TAC combined with MMF can be considered as an alternative therapeutic option for children with refractory lupus nephritis particularly those with persistent nephrotic-range proteinuria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijpam.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T11:37:40Z","timestamp":1533814660000},"page":"99-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis"],"prefix":"10.4103","volume":"5","author":[{"given":"Abdulaziz","family":"Almutairi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyad","family":"Alkathiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman M.","family":"Al-Mayouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240319","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/0961203313502863","article-title":"Children and adolescents with SLE: not just little adults","volume":"22","author":"Morgan","year":"2013","journal-title":"Lupus"},{"key":"R2-4-20240319","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrrheum.2010.121","article-title":"Prevalence and burden of pediatric-onset systemic lupus erythematosus","volume":"6","author":"Kamphuis","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R3-4-20240319","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2013.07.005","article-title":"Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions","volume":"43","author":"Wu","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R4-4-20240319","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/0961203312443421","article-title":"Lupus nephritis is more severe in children and adolescents than in older adults","volume":"21","author":"Sato","year":"2012","journal-title":"Lupus"},{"key":"R5-4-20240319","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3899\/jrheum.170502","article-title":"Approach to membranous lupus nephritis: a survey of pediatric nephrologist and pediatric rheumatologists","volume":"44","author":"Boneparth","year":"2017","journal-title":"J Rheumatol"},{"key":"R6-4-20240319","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00467-017-3767-4","article-title":"Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis","volume":"33","author":"Hogan","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"R7-4-20240319","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendation for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R8-4-20240319","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-4-20240319","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: a systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R10-4-20240319","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0961203318758505","article-title":"Outcome of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis","volume":"27","author":"Choi","year":"2018","journal-title":"Lupus"},{"key":"R11-4-20240319","first-page":"378","article-title":"The role of tacrolimus in the step-up induction therpay of refractory childhood-onset lupus nephritis","volume":"19","author":"Chatzidmitriou","year":"2015","journal-title":"Hippokratia"},{"key":"R12-4-20240319","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/0961203307081914","article-title":"Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study","volume":"16","author":"Tanaka","year":"2007","journal-title":"Lupus"},{"key":"R13-4-20240319","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000346149","article-title":"Long-Term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice clinical practice","volume":"121","author":"Tanaka","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"R14-4-20240319","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10157-017-1381-1","article-title":"Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy","volume":"2","author":"Tanaka","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"R15-4-20240319","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R16-4-20240319","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40620-014-0157-x","article-title":"Lupus nephritis in Egyptian children: a 16-year experience","volume":"28","author":"Elmougy","year":"2015","journal-title":"J Nephrol"},{"key":"R17-4-20240319","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00296-013-2896-8","article-title":"Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus","volume":"34","author":"Ale'ed","year":"2014","journal-title":"Rheumatol Int"},{"key":"R18-4-20240319","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00467-017-3767-4","article-title":"Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis","volume":"33","author":"Hogan","year":"2018","journal-title":"Pediatr Nephorl"},{"key":"R19-4-20240319","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/rheumatology\/keu265","article-title":"Long-term data on tacrolimus treatment in lupus nephritis","volume":"53","author":"Yap","year":"2014","journal-title":"Rheumatology"},{"key":"R20-4-20240319","doi-asserted-by":"crossref","first-page":"8130","DOI":"10.1177\/0961203314528553","article-title":"Efficacy of mizoribine-tarcolimus-based induction therapy for pediatric lupus nephritis","volume":"23","author":"Tanaka","year":"2014","journal-title":"Lupus"},{"key":"R21-4-20240319","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0961203318758505","article-title":"Outcomes of mutlitarget therapy using mycophenolate mofetil and tracolimus for refractory or relapsing lupus nephritis","volume":"27","author":"Choi","year":"2018","journal-title":"Lupus"}],"container-title":["International Journal of Pediatrics and Adolescent Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646718300887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646718300887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01863514-201805030-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:24:59Z","timestamp":1786724699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01863514-201805030-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijpam.2018.08.001","relation":{},"ISSN":["2352-6467"],"issn-type":[{"value":"2352-6467","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pediatrics and Adolescent Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpam.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia.","name":"copyright","label":"Copyright"}]}}